A5025583189- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
- Virus-based gene therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 detection and testing
- Virology and Viral Diseases
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Vaccine Coverage and Hesitancy
Copenhagen University Hospital
2021-2024
Herlev Hospital
2023
University of Copenhagen
2020-2021
Abstract The rapid development of a SARS-CoV-2 vaccine is global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) spike protein. RBD antigens are displayed on AP205 CLPs through split-protein Tag/Catcher, ensuring unidirectional and high-density display RBD. Both soluble recombinant bind ACE2 receptor with nanomolar affinity. Mice vaccinated or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. RBD-CLP induce higher...
Capsid virus-like particles (cVLP) have proven safe and immunogenic can be a versatile platform to counter pandemics. We aimed clinically test modular cVLP COVID-19 vaccine in individuals who were naive SARS-CoV-2.In this phase 1, single-centre, dose-escalation, adjuvant-selection, open-label clinical trial, we recruited participants at the Radboud University Medical Center Nijmegen, Netherlands, sequentially assigned them seven groups. Eligible healthy, aged 18-55 years, tested negative for...
The past decades of cancer immunotherapy research have provided profound evidence that the immune system is capable inducing durable tumor regression. Although many commercialized anti-cancer immunotherapies are available to patients, these treatment options only scrape surface potential immune-related possibilities for cancer. Additionally, individuals ineligible established due their type. adoptive cell transfer autologous tumor-infiltrating lymphocytes has been used in humans over 30...
Abstract The rapid development of a SARS-CoV-2 vaccine is global priority. Here, we developed two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) spike protein. RBD antigens were displayed on AP205 CLPs through novel split-protein Tag/Catcher ensuring unidirectional and high-density display RBD. Both soluble recombinant RBD, bound ACE2 receptor with nanomolar affinity. Mice vaccinated or CLP-displayed formulated in Squalene-Water-Emulsion. RBD-CLP...
<h3>Background</h3> Adoptive cell therapy (ACT) using <i>ex vivo</i> expanded tumor-infiltrating lymphocytes (TILs) has repeatedly mediated durable responses in patients with metastatic melanoma,<sup>1</sup> even after failure of prior immunotherapies.<sup>2 3</sup> However, its adaptation to other cancer types remains a key challenge. Ovarian is marked by high mortality rates, primarily due late-stage diagnosis and treatment resistance. While anti-PD1 been approved for TMB-/MSI-high ovarian...
Abstract Cellular effector function assays traditionally rely on bulk cell populations that mask complex heterogeneity and rare subpopulations. The Xdrop® droplet technology facilitates high-throughput compartmentalization of viable single cells or single-cell pairs in double-emulsion droplets, enabling the study cell-cell interactions at an individual level. Effector molecule secretion target killing can be evaluated independently combination. Compatibility with a wide range commercial...
Checkpoint inhibition (CPI) therapy and adoptive cell with autologous tumor-infiltrating lymphocytes (TIL-based ACT) are the two most effective immunotherapies for treatment of metastatic melanoma. While CPI has been dominating in past decade, TIL-based ACT is beneficial individuals even after progression on previous immunotherapies. Given that notable differences response have made when used as a subsequent treatment, we investigated how qualities TILs changed ex vivo microenvironment...
<h3>Background</h3> Adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TILs) is an effective for advanced melanoma, response rates between 30–50%.<sup>1 2</sup> However, the majority of patients do not respond, and immunological targets TIL TCRs remain elusive.<sup>3</sup> Dark Antigens are cancer specific discovered in regions genome historically considered noncoding. Due to their intratumoral homogeneity shared expression individuals, they make attractive...